T3D Therapeutics
Roger Bullock has over 30 years of clinical research experience, largely in Dementia clinical trials at the Kingshill Research Center, which he founded. During that time he published over 100 peer-reviewed publications and regularly presented at international conferences. Currently, he is working in drug development in the biotech space and has been involved in several projects, including T3D. After many years in the clinical field, he is now devoting his energy towards tackling the mechanisms of neurodegeneration in the hope of making a major impact in this area of unmet medical need.
This person is not in the org chart
This person is not in any offices
T3D Therapeutics
T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.